Navigation Links
Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Date:10/12/2010

AURORA, Ontario, Oct. 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.   These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.  

The Company plans to conduct a Phase I study in the U.S. in patients with refractory solid tumors and a  Phase I/II, multi-arm safety and preliminary efficacy study in patients with stage III/IV non-small cell lung cancer in Poland.  It intends to use the findings from its GLP toxicology studies to complete the necessary protocol designs and other supportive documentation, as final steps in preparing its U.S. Phase I IND and its Polish Phase I/II CTA dossiers.  As a result of some delays in completing its GLP toxicology studies, Helix now expects these IND/CTA submissions to be made in its second rather than its first quarter of fiscal 2011.  

"We are very pleased to reach this important clinic-enabling milestone in our L-DOS47 development program," said John Docherty, Helix president and COO.  "Having completed these studies, Helix believes it now has a sufficient preclinical pharmacology and toxicology database to support human clinical testing with this important new drug candidate.  Helix is committed to completing these submissions as soon as possible, as it is no longer waiting for any further preclinical study findings before doing so."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new dr
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix Biopharma Closes $11.4 Million Private Placement
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
6. Helix BioPharma Announces Q1 2009 Financial Results
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Announces Q2 2009 Financial Results
11. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... July 24, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the Company ... June 30, 2014 on Monday, August 18, 2014 for ... a.m. ET on Monday, August 18, 2014 to discuss ... the company,s CEO, Anthony Hayes . ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Spherix Schedules Shareholder Update Call 2
... Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE ), today ... securities purchase agreement (the "Agreement") with Robert Gipson for the ... Company at a purchase price of $1.00 per share. ... In connection with the Agreement, Mr. Gipson agreed to ...
... Jan. 13 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... announced that it has been granted its 31st ... Treatment of Neoplasia." The patent includes claims to ... expands and strengthens our proprietary position for REOLYSIN(R)," ...
... TORONTO, Jan. 13 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... tests for the early detection of diseases and ... granted U.S. Patent # 7,473,528 entitled "Method for ... in blood". This patent protects the Company,s discovery ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 2
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... for an all-day public forum on a $1.7 billion ... dredge toxic sediment from an eight-mile stretch of the ... plan, which proposes removing 4.3 million cubic yards of ... of the largest cleanups in the agency,s history. The ... "We need to ensure the future well-being of humans ...
(Date:7/24/2014)... Calif. -- To reduce fire hazard in the United ... mechanically cutting woody shrubs and suppressed trees (ladder fuels). ... burned during periods of low fire danger in order ... and minimize hazardous air pollutants, managers often cover all ... plastic, commonly referred to as agricultural plastic, in order ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... interface and DNA self-assembly techniques, researchers have developed ... drastically reduce the time required to create and ... National Science Foundation (NSF) Small Business Innovation Research ... recently developed and began evaluating a drug for ...
... has found that the impacts of climate change on ... site to site and from species to species., While ... upslope, others will move downslope, driven by changes in ... predicted variation, together with the long-term isolation and relative ...
... BONESUPPORT, chef de file émergent dans les ... les infections osseuses et l,augmentation des instruments ... aujourd,hui qu,elle a été sélectionnée comme un ... Red Herring 2012 dans la reconnaissance en tant ...
Cached Biology News:Drag-and-drop DNA 2Drag-and-drop DNA 3Drag-and-drop DNA 4Researchers investigate impacts of climate change on rare tropical plants 2Researchers investigate impacts of climate change on rare tropical plants 3BONESUPPORT sélectionné en tant que 100 meilleures entreprises mondiales du Red Herring 2012 2BONESUPPORT sélectionné en tant que 100 meilleures entreprises mondiales du Red Herring 2012 3
... GCpro Taq DNA Polymerase is a ... advantages for all PCR applications. GCpro Taq ... clone expressed in E. coli, containing the ... The enzyme includes a highly processive 5'-3' ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Biology Products: